TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21515398
Drug: Beta-glucan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan (3 g/d)
Study: 19112336
Drug: Etodolac (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (400 mg/d)
Study: 16014819
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and nutrition treatment (nutrition counseling and child behavioral management training for parents)
Study: 11789748
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement
Study: 11789748
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement
Study: 1314337
Drug: Methoxamine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine (intravenous administration)
Study: 1314337
Drug: Norepinephrine (NE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (NE, intravenous administration)
Study: 3908131
Drug: iodopropylidene glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodopropylidene glycerol (IPG-Organidin), two tablets four times daily
Study: 30620140
Drug: Preoperative topical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate (10 mg/ml) and nepafenac (1 mg/ml)
Study: 30620140
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative anti-inflammatory treatment
Study: 30620140
Drug: Preoperative topical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate and nepafenac
Study: 23321182
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg orally once daily
Study: 23321182
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg orally twice daily
Study: 19087678
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus continuous renal replacement therapy (CRRT)
Study: 16238122
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of xanthan gum with test meal (ham sandwich - 90 kcal)
Study: 9952140
Drug: Air therapy
Normalized name: Amlactin Foot Repair Therapy 15% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air therapy (control)
Study: 1971660
Drug: Cholestyramine or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine or Pravastatin treatment
Study: 30048324
Drug: Low-dose contrast
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose contrast enhanced CT
Study: 28940815
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, pantoprazole 40 mg twice daily for 10 days)
Study: 28940815
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (amoxicillin 1000 mg with pantoprazole 40 mg twice daily for 5 days, followed by clarithromycin 500 mg with metronidazole 500 mg and pantoprazole 40 mg twice daily for 5 days)
Study: 28940815
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy in clarithromycin-resistant strains
Study: 28940815
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy in clarithromycin-resistant strains
Study: 22868243
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m² twice daily on days 1‐14 (Arm A)
Study: 22868243
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m² twice daily on days 1‐14, oxaliplatin 100 mg/m² on day 1 initially, 130 mg/m² for subsequent cycles (Arm B)
Study: 19053049
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg three times a day) with a 1,400 Kcal/day diet plus vitamin E (800 IU) daily
Study: 19053049
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus vitamin E (800 IU) daily
Study: 11157603
Drug: Moxifloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin, 400 mg/d for 10 days
Study: 11157603
Drug: Amoxicillin, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 1,000 mg tid for 10 days
Study: 25829373
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g/8 h)
Study: 9593156
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g/8 h) plus Gentamicin (4 mg/kg daily)
Study: 7921936
Drug: Modified Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Needle Suspension (MNS)
Study: 2848900
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of oral acyclovir, twice daily for one year
Study: 2848900
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for one year
Study: 29636004
Drug: Central venous
Normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central venous administration of sufentanil (group CV)
Study: 29636004
Drug: Peripheral venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral venous administration of sufentanil (group PV)
Study: 26628268
Drug: Internet-delivered six-lesson
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered six-lesson 10-week cognitive behavioural therapy (iCBT) intervention for PTSD
Study: 23987791
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus standard antiemetic therapy (ondansetron plus dexamethasone)
Study: 18771232
Drug: Intensive glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose-lowering therapy (HbA1c < 6%) in ACCORD trial
Study: 18771232
Drug: Intensive glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose-lowering therapy (HbA1c ≤ 6.5%, modified release gliclazide as main treatment) in ADVANCE trial
Study: 18771232
Drug: Intensive glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose-lowering therapy in VA-Diabetes trial
Study: 15705991
Drug: Inhaled colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled colistin (75 mg in 4 mL saline solution)
Study: 10564839
Drug: Aerosolized ABT-431
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized ABT-431 (5 mg); C(max) was 13.3±0.9 ng/ml and AUC(0-24) was 33.2±10.6 h ng/ml in dogs.
Study: 10564839
Drug: Oral inhalation
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation of ABT-431 (dosage levels between 3.3 and 13.2 mg); demonstrated rapid absorption and dose-dependent increase in AUC.
Study: 1746653
Drug: AIDS education,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDS education, HIV antibody test, and test results
Study: 6269770
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, and Adriamycin (VOCA)
Study: 6269770
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, Adriamycin (VOCA) plus low-dose (40 mg/m2) cisplatin (VOCAP)
Study: 25918277
Drug: PediQUEST Memorial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PediQUEST Memorial Symptom Assessment Scale (PQ‐MSAS) administered 920 times
Study: 25918277
Drug: Mild cancer‐directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild cancer‐directed therapy in the final 12 weeks of life
Study: 23602942
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) program, 12 sessions
Study: 21347803
Drug: Tacrolimus 3
Normalized name: Tacrolimus 300 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 3 mg once daily for 52 weeks
Study: 19081190
Drug: Topical high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical high concentration (10%) capsaicin
Study: 19081190
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three GCH1 SNPs
Study: 15638906
Drug: Vardenafil 5
Normalized name: vardenafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 5 mg
Study: 16422973
Drug: Vardenafil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (all doses)
Study: 8510708
Drug: Inhaled heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled heparin (1000 U per kilogram)
Study: 6412606
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (20 mg)
Study: 3548314
Drug: Aminoglutethimide and
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide and hydrocortisone plus Estrace 2 mg b.i.d. sublingually for 3 days before and on the day of chemotherapy
Study: 3548314
Drug: Aminoglutethimide and
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide and hydrocortisone plus cyclic chemotherapy (control group)
Study: 27039081
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 40 mg/28 days
Study: 27039081
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 20 mg/28 days
Study: 11339108
Drug: hydrogen reduced
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrogen reduced iron plus ascorbic acid (15 mg)
Study: 3588053
Drug: Piperacillin 600
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin 600 mg/kg/day
Study: 3588053
Drug: Piperacillin 900
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin 900 mg/kg/day
Study: 3588053
Drug: Piperacillin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (total daily dosages)
Study: 28497478
Drug: Dapoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine (30 mg)
Study: 28497478
Drug: Combined dapoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dapoxetine (30 mg) with sildenafil citrate (50 mg)
Study: 28169811
Drug: Pediatric Peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric Peripheral Intravenous Infiltration Scale (PIV Scale)
Study: 17922612
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (2 g/d)
Study: 15540741
Drug: Bicalutamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (150 mg)
Study: 11386498
Drug: Inositol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (up to 18 g/day)
Study: 7956987
Drug: Oat gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat gum (2.9 g beta-glucan)
Study: 3602212
Drug: Bromocriptine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (single dose)
Study: 23239139
Drug: Losmapimod, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod, 7.5 mg BID for 28 days
Study: 21689371
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 7500 IU twice daily until birth or 34 weeks
Study: 16940833
Drug: Seven‐valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven‐valent pneumococcal conjugate vaccine
Study: 9180362
Drug: THC (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (lower dose)
Study: 9180362
Drug: THC (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (higher dose)
Study: 27604532
Drug: Intramuscular group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular group (intramuscular injection of betamethasone and US-guided intratenosynovial isotonic saline injection)
Study: 27604532
Drug: Intratenosynovial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratenosynovial group (saline intramuscularly and US-guided intratenosynovial betamethasone injection)
Study: 24565123
Drug: Ketamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (5 mcg.kg(‐1).min(‐1)) and remifentanil (0.4 mcg.kg(‐1).min(‐1))
Study: 24565123
Drug: Remifentanil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.4 mcg.kg(‐1).min(‐1)) and saline solution
Study: 21885625
Drug: Long-acting β-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β-agonists
Study: 17321595
Drug: Clinical management/pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management/pharmacotherapy
Study: 17321595
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance IPT/pharmacotherapy
Study: 17321595
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance IPT/placebo
Study: 15204461
Drug: Electromagnetic field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromagnetic field treatment with calcitonin and exercise
Study: 15204461
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with calcitonin and exercise
Study: 11355928
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 daunorubicin for 3 days in combination with standard dose Ara‐C and 6‐thioguanine for induction and consolidation, followed by prolonged monthly maintenance chemotherapy for at least 1 year.
Study: 9476677
Drug: High‐dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose fentanyl anaesthesia (group II)
Study: 30721998
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy interventions; details on dosage and duration not available.
Study: 30721998
Drug: Training music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training music intervention providers; details on dosage and duration not available.
Study: 30721998
Drug: Intervention delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention delivery supervision; details on dosage and duration not available.
Study: 30721998
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of intervention protocol adherence; details on dosage and duration not available.
Study: 28159015
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg IC43 without adjuvant
Study: 28159015
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg IC43 with adjuvant
Study: 28159015
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg IC43 with adjuvant
Study: 24444353
Drug: PEG‐IFN therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN therapy
Study: 17013468
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg melatonin and 50 mg zinc acetate
Study: 17013468
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg melatonin and 50 mg zinc acetate in addition to metformin
Study: 14960215
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) for insomnia (comprising sleep hygiene, stimulus control, relaxation and cognitive therapy components)
Study: 14960215
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) for insomnia
Study: 10417577
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (control group)
Study: 8706196
Drug: Pre‐induction volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐induction volume loading (12 ml x kg(‐1) Ringer's lactate)
Study: 2194304
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (2 x 1.2 Gy/day, five days/week, total dose 74.4 to 79.2 Gy) with simultaneous Cisplatinum (20 mg/m2 day, i.v., five days in the first and fifth week of the radiotherapy)
Study: 157893
Drug: Vioform cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vioform cream, Locacorten‐Vioform cream, Vioform‐Hydrocortisone cream (topical application of 30 mg clioquinol each)
Study: 157893
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of clioquinol (30 mg)
Study: 31186189
Drug: Intervention (vaccine)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention (vaccine) risk video
Study: 27380904
Drug: CCTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCTA with IV nitrate infusion
Study: 25347938
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ipragliflozin
Study: 24598046
Drug: Intranasal Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Ketamine (2 mg/kg) and Midazolam (0.5 mg/kg)
Study: 24598046
Drug: Intranasal Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Ketamine and Midazolam
Study: 18841327
Drug: Weekly oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly oxaliplatin 60 mg/m(2) and 5-fluorouracil 225 mg/m(2) daily throughout radiation therapy
Study: 9806255
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg Cetrorelix
Study: 9806255
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg Cetrorelix
Study: 9806255
Drug: 1.00 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.00 mg Cetrorelix
Study: 7700286
Drug: No myelosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No myelosuppressive therapy (Control)
Study: 29778918
Drug: SHUTi (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHUTi (internet-based cognitive behavioral therapy for insomnia)
Study: 24237188
Drug: PC-18 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-18 at 37.5 mg by mouth two times per day (PO bid) for 3 weeks (induction phase)
Study: 24237188
Drug: PC-18 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-18 at the same dose (37.5 mg PO bid) during the maintenance phase
Study: 20958145
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (CT) with allopurinol (100‐200 mg/day) and citrate preparation (3 g/day) for 12 weeks
Study: 20958145
Drug: Allopurinol monotherapy
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol monotherapy (MT) (100‐200 mg/day) for 12 weeks
Study: 20958145
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (CT) with allopurinol and citrate preparation
Study: 20958145
Drug: Allopurinol monotherapy
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol monotherapy (MT)
Study: 17145540
Drug: Three-Dimensional Conformal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Study: 12932071
Drug: Propofol 15
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 15 mg (1.5 mL) in Group P
Study: 12932071
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 mg in Group M1
Study: 12932071
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg in Group M2
Study: 12932071
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg in Group O
Study: 26053341
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (endotracheal intubation during mechanical ventilation)
Study: 23782463
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg) added to treatment as usual
Study: 23782463
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg OD, increased to 40 mg after 4 weeks) added to treatment as usual
Study: 23782463
Drug: Ondansetron and
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron and Simvastatin added to treatment as usual
Study: 20230405
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m² on days 1, 3, and 5 (arm A)
Study: 20230405
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 6 mg/m² on day 1 and 3 mg/m² on day 8 (arm B)
Study: 18986292
Drug: Blinding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinding of clinical trial participants and study drug assignment